$SMTI Income Statement | Understand Stock

$SMTI

$32.84 -$0.18 (0.55%) Close

$SMTI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Net revenue
Cost of goods sold
Gross profit
Operating expenses
Selling, general and administrative expenses
Selling, general and administrative
Research and development
Depreciation and amortization
Change in fair value of earnout liabilities
Asset impairment charges
Total operating expenses
Operating income
Other income (expense)
Interest expense
Share of losses from equity method investments
Interest income
Gain on disposal of investment
Gain on disposal of property and equipment
Total other income (expense)
Loss before income taxes
Income tax benefit
Net loss from continuing operations
Net loss from discontinued operations (including asset impairment charge of $26,472,407 in 2025) (Note 3)
Net loss
Net loss attributable to noncontrolling interest from continuing operations
Net loss attributable to noncontrolling interest from discontinued operations
Less: Total net loss attributable to noncontrolling interest
Net loss attributable to Sanara MedTech common shareholders
Net loss per share of common stock, basic and diluted
Weighted average number of common shares outstanding, basic and diluted
Net loss attributable to Sanara MedTech shareholders
Net loss per share, basic and diluted:
Continuing operations, basic
Continuing operations, diluted
Discontinued operations, basic
Discontinued operations, diluted
Net loss per share of common stock, basic
Net loss per share of common stock, diluted
Weighted average number of common shares outstanding, basic
Weighted average number of common shares outstanding, diluted

Comments